Added to YB: 2025-10-22
Pitch date: 2025-10-20
SOBI.ST [neutral]
Swedish Orphan Biovitrum AB (publ)
+30.9%
current return
Author Info
Nordic Edge provides actionable insights and alpha-generating opportunities in the Nordics. Sign up for the newsletter.
Company Info
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
Market Cap
SEK 123.5B
Pitch Price
SEK 306.80
Price Target
N/A
Dividend
N/A
EV/EBITDA
12.22
P/E
261.61
EV/Sales
4.74
Sector
Biotechnology
Category
growth
Swedish Orphan Biovitrum (SOBI) Q3-2025 Earnings Review
SOBI.ST (earnings): Q3 rev SEK 7,776m (+13% y/y, +21% CC) beat on Altuvoct/Doptelet strength; FY25 guidance raised to LDD growth & mid-to-high 30s EBITA margin. Vonjo disappointment led to SEK 6.6bn impairment. Beyfortus royalty weak on slow RSV season. Strong FCF generation continues.
Read full article (2 min)